Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing chemotherapy and targeted agent combinations in NSCLC.

Thomas Lynch1, Edward Kim

  • 1Massachusetts General Hospital, Boston, MA 02114, USA. tlynch@partners.org

Lung Cancer (Amsterdam, Netherlands)
|March 25, 2006
PubMed
Summary

Chemotherapy offers survival and symptom relief for advanced non-small cell lung cancer (NSCLC). While many regimens show similar efficacy, bevacizumab combined with chemotherapy improved survival in specific NSCLC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fast large scale full-wave multiple-scattering computation for three-dimensional random rough surfaces.

Scientific reports·2026
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Age-related differences in psychological distress and persistent postsurgical pain after surgery for management of non-invasive breast lesions.

Breast cancer research and treatment·2026
Same author

How I Do It: "And That's a BINGO!" Using a Self-Directed, Gamified Instrument to Structure Learning on the Obstetrics Clerkship.

Journal of surgical education·2026
Same author

[<sup>68</sup>Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.

Radiology·2026

Area of Science:

  • Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Chemotherapy is a standard treatment for advanced non-small cell lung cancer (NSCLC), offering survival extension and symptom palliation.
  • Despite numerous trials, traditional cytotoxic chemotherapy regimens have reached a plateau in improving survival rates.
  • The addition of targeted agents to chemotherapy has largely failed to demonstrate significant survival benefits in advanced NSCLC.

Purpose of the Study:

  • To review the current landscape of chemotherapy and targeted agent combinations for advanced non-small cell lung cancer (NSCLC).
  • To identify specific treatment strategies that have shown efficacy, such as bevacizumab in non-squamous NSCLC.
  • To discuss rational approaches for future drug development and combination therapies in advanced NSCLC.

Main Methods:

Related Experiment Videos

  • Review of clinical trial data evaluating chemotherapy doublets and targeted agents in advanced NSCLC.
  • Analysis of efficacy and survival data from key trials, including E4599.
  • Discussion of preclinical modeling and ongoing trials combining novel agents with chemotherapy.

Main Results:

  • Most chemotherapy doublet regimens show similar efficacy in advanced NSCLC.
  • Erlotinib or gefitinib added to chemotherapy did not improve survival, but erlotinib monotherapy showed benefit in later lines of treatment.
  • Bevacizumab added to paclitaxel-carboplatin chemotherapy extended survival in patients with non-squamous NSCLC.

Conclusions:

  • Bevacizumab's success in E4599 highlights the importance of large, randomized trials for identifying patient subgroups and potential toxicities (e.g., squamous cell carcinoma).
  • Future strategies involve selecting synergistic chemotherapy backbones (e.g., docetaxel, carboplatin-paclitaxel, cisplatin-gemcitabine) for combination with novel agents.
  • Ongoing trials are exploring combinations with EGFR inhibitors, VEGF inhibitors, proteasome inhibitors, COX2 inhibitors, and immunomodulators.